Protect Pharmaceutical Corp. Announces New President Ali Yildiz
Protect Pharmaceutical Corp. (PRTT) announces a significant change in control of its Preferred Series A shares and the appointment of Ali Yildiz as the new president. Yildiz, who has a proven track record in scaling companies, aims to enhance growth and stability. He is finalizing the acquisition of Antarax Capital Danismanlik Limited, a Turkish firm focused on logistics, which is anticipated to bring substantial shareholder value. This acquisition reflects the company's strategic moves to strengthen its position. Yildiz has expressed commitment to transparency with shareholders and will provide updates through OTC filings.
- Appointment of Ali Yildiz as president, bringing extensive experience.
- Planned acquisition of Antarax Capital Danismanlik Limited, expected to enhance shareholder value.
- None.
Istanbul, Turkey, March 08, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” announces the change of control of the Preferred series A shares and the appointment of a new president, Ali Yildiz. Aetsoft, as previously announced, has been divested from the company.
Mr. Yildiz brings a wealth of knowledge and experience to the company. Mr. Yildiz has an impressive track record growing companies on a large scale and is looking forward to bringing his skill to create growth and stability for Protect Pharmaceutical.
Mr. Yildiz is currently finalizing the acquisition of Antarax Capital Danismanlik Limited and feels that this acquisition will provide excellent shareholder value. Antarax Capital Danismanlik Limited is a Turkish Corporation specializing in transportation and storage of import and export goods. Mr. Yildiz stated “The company expects to complete filings with OTC in the next few weeks and will provide more specific details through filings and will also communicate further with our shareholders. I have personally been involved in several acquisitions and mergers and I am excited to lead the company in this new direction.”
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
Protect Pharmaceutical Corp.
(347) 692 8942
business@inaiapp.com
FAQ
What are the recent developments at Protect Pharmaceutical Corp. (PRTT)?
Who is the new president of Protect Pharmaceutical Corp.?
What acquisition is Protect Pharmaceutical Corp. pursuing?
How does the acquisition of Antarax Capital benefit PRTT shareholders?
When can shareholders expect updates on Protect Pharmaceutical Corp.'s activities?
